Sugi Predict

Sugi Predict / Compounds / SCHEMBL436278

SCHEMBL436278

SCHEMBL436278

COC(=O)c1cccc(OS(=O)(=O)C(F)(F)F)c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ LMNA P02545 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ SLC6A3 Q01959 2/20 0.43
▸ CXCR2 P25025 1/20 0.41
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ CA9 Q16790 2/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41
▸ CA5A P35218 1/20 0.41
▸ MAPT P10636 2/20 0.40
▸ MITF O75030 1/20 0.40
▸ PDK2 Q15119 3/20 0.39
▸ SLC6A4 P31645 1/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ CFTR P13569 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4442981 0.87 L3MBTL1 (0.61) L3MBTL1LMNATSHRSLC6A3CA1
SCHEMBL16056779 0.86 L3MBTL1 (0.47) L3MBTL1LMNATSHRSLC6A3CA1
SCHEMBL21121087 0.84 PDK2 (0.48) L3MBTL1LMNATSHRSLC6A3CA1
SCHEMBL5674574 0.82 GAA (0.46) L3MBTL1LMNATSHRSLC6A3CA1
SCHEMBL7423216 0.81 L3MBTL1 (0.43) L3MBTL1LMNATSHRSLC6A3CA1
SCHEMBL24436792 0.79 KCNK3 (0.50) L3MBTL1LMNATSHRSLC6A3CXCR2
SCHEMBL3095236 0.78 GRIN2D (0.45) L3MBTL1LMNATSHRCA1CA2
SCHEMBL7214605 0.78 KDM4E (0.49) L3MBTL1SLC6A3MAPTPDK2KMT2A
SCHEMBL4634707 0.77 EPAS1 (0.47) L3MBTL1LMNASLC6A3CXCR2PDK2
SCHEMBL6704761 0.77 LMNA (0.42) L3MBTL1LMNATSHRSLC6A3CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034105-A1 Generative AI-Assisted Identification of Novel PI3K-alpha Inhibitors THE FIRST AFFILIATED HOSPITAL OF XI'AN JIAOTONG UNIVERSITY (CN) 2026-02-05 — — US disclosed
EP-2406258-B1 PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS CELLZOME LTD (GB) 2014-12-03 — — EP disclosed
US-20140296234-A1 PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS CELLZOME LIMITED 2014-10-02 — — US disclosed
US-8785457-B2 Pyrimidine derivatives as mTOR inhibitors CELLZOME LIMITED (GB) 2014-07-22 — — US disclosed
US-20120237533-A1 Compositions and Methods for Inducing Apoptosis in Prostate Cancer Cells WAKE FOREST UNIVERSITY HEALTH SCIENCES 2012-09-20 — — US disclosed
US-20120237533-A1 Compositions and Methods for Inducing Apoptosis in Prostate Cancer Cells WAKE FOREST UNIVERSITY HEALTH SCIENCES 2012-09-20 — — US disclosed
US-20120065202-A1 PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS CELLZOME LIMITED (GB) 2012-03-15 — — US disclosed
EP-2410062-A1 Selectivity profiling of PI3K interacting molecules against multiple targets CELLZOME AG (DE) 2012-01-25 — — EP disclosed
EP-2410062-A1 Selectivity profiling of PI3K interacting molecules against multiple targets CELLZOME AG (DE) 2012-01-25 — — EP disclosed
EP-2406258-A1 PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS Cellzome Limited (GB) 2012-01-18 — — EP disclosed
US-7226918-B2 DNA-PK inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-06-05 — — US disclosed
EP-1257537-B1 THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS ASTRAZENECA AB (SE) 2007-05-30 — — EP disclosed
US-6977255-B2 Therapeutic morpholino-substituted compounds KINACIA PTY. LTD. (AU) 2005-12-20 — — US disclosed
US-20050085471-A1 Therapeutic morpholino-substituted compounds KINACIA PTY LTD. 2005-04-21 — — US disclosed
US-20040192687-A1 Dna-pk inhibitors CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 2004-09-30 — — US disclosed
EP-1417196-A1 DNA-PK INHIBITORS Cancer Research Technology Limited (GB) 2004-05-12 — — EP disclosed
EP-1257537-A4 THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS KINACIA PTY LTD (AU) 2003-04-23 — — EP disclosed
WO-2003024949-A1 DNA-PK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2003-03-27 — — WO disclosed
EP-1257537-A1 THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS Kinacia Pty Ltd (AU) 2002-11-20 — — EP disclosed
WO-2001053266-A1 THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS KINACIA PTY LTD. (AU) 2001-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085471-A1 Therapeutic morpholino-substituted compounds PIK3CA, PTK2, PDPK1 L3MBTL1 1690/4885LMNA 4199/4885TSHR 3706/4885
US-20260034105-A1 Generative AI-Assisted Identification of Novel PI3K-alpha Inhibitors PIK3R1, PIK3R4, PIK3R2 L3MBTL1 1184/4885LMNA 4236/4885TSHR 1194/4885
US-20120065202-A1 PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR L3MBTL1 3134/4885LMNA 2684/4885TSHR 2833/4885
US-20040192687-A1 Dna-pk inhibitors ATM, CHEK1, XRCC6 L3MBTL1 2433/4885LMNA 993/4885TSHR 2010/4885
US-20140296234-A1 PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS MTOR, RICTOR, RPTOR L3MBTL1 3134/4885LMNA 2684/4885TSHR 2833/4885
US-20120237533-A1 Compositions and Methods for Inducing Apoptosis in Prostate Cancer Cells BAX, CASP3, BCL2 L3MBTL1 1409/4885LMNA 208/4885TSHR 4813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.